- Home
- MCRB vs MSD Comparison
MCRB vs MSD Comparison
Compare MCRB & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MSD
- Stock Information
- Founded
- MCRB 2010
- MSD 1993
- Country
- MCRB United States
- MSD United States
- Employees
- MCRB N/A
- MSD N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MSD Trusts Except Educational Religious and Charitable
- Sector
- MCRB Health Care
- MSD Finance
- Exchange
- MCRB Nasdaq
- MSD Nasdaq
- Market Cap
- MCRB 142.0M
- MSD 164.6M
- IPO Year
- MCRB 2015
- MSD N/A
- Fundamental
- Price
- MCRB $0.85
- MSD $7.91
- Analyst Decision
- MCRB Buy
- MSD
- Analyst Count
- MCRB 4
- MSD 0
- Target Price
- MCRB $4.17
- MSD N/A
- AVG Volume (30 Days)
- MCRB 5.4M
- MSD 70.2K
- Earning Date
- MCRB 10-31-2024
- MSD 01-01-0001
- Dividend Yield
- MCRB N/A
- MSD 11.26%
- EPS Growth
- MCRB N/A
- MSD N/A
- EPS
- MCRB N/A
- MSD N/A
- Revenue
- MCRB $374,000.00
- MSD N/A
- Revenue This Year
- MCRB N/A
- MSD N/A
- Revenue Next Year
- MCRB N/A
- MSD N/A
- P/E Ratio
- MCRB N/A
- MSD N/A
- Revenue Growth
- MCRB N/A
- MSD N/A
- 52 Week Low
- MCRB $0.54
- MSD $6.11
- 52 Week High
- MCRB $2.06
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- MCRB 42.22
- MSD 50.80
- Support Level
- MCRB $0.80
- MSD $7.85
- Resistance Level
- MCRB $1.07
- MSD $8.00
- Average True Range (ATR)
- MCRB 0.12
- MSD 0.10
- MACD
- MCRB -0.02
- MSD -0.03
- Stochastic Oscillator
- MCRB 12.26
- MSD 16.72
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.